Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China SFDA Generics Report Acknowledges Industry And Regulator Have A Long Road Ahead

This article was originally published in PharmAsia News

Executive Summary

A rare government report criticizes practices of China’s generics industry and SFDA, officially highlighting well-recognized problems – from a lengthy registration process to a lack of pricing and bidding incentives – which need urgent attention.

You may also be interested in...



FDA Generics Office Hopes To Begin Increasing Staff By Year-End

To aid in ANDA assignments, OGD is developing a program to prioritize submissions as the agency addresses a 3,000-application backlog, OGD Deputy Director Robert West says during regulatory affairs specialists’ gathering in Seattle.

What Lies Beneath China's Steep Price Cuts For New Drugs

Prices of  direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature. 

Asia Executives On The Move: BMS, Pfizer, Takeda, RDPAC

Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.

Topics

Related Companies

UsernamePublicRestriction

Register

SC079961

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel